时间标签：数据日期 2026-11-03 · 生成时间 2026-11-03 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/31 – 2026/11/03 ｜ 情报发生日期 2026-11-03
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
摘要（PubMed 原文节选）
Calcific aortic valve disease (CAVD) is the most prevalent valvular heart disease in the Western countries and carries significant morbidity and mortality, yet no pharmacological therapy has demonstrated efficacy in modifying its natural history. Once regarded as a passive degenerative process, CAVD is now recognized as an actively regulated disease driven by endothelial dysfunction, chronic inflammation, dysregulated mineral metabolism, and cellular senescence, which collectively drive progressive fibrotic remodeling and calcification of the valve leaflets through both dystrophic and osteogenic mechanisms. This review examines the pharmacological strategies that have been investigated or ar…
对本项目的价值
中等价值：属「衰老细胞清除 / SASP 轴」方向；干预策略与临床试验栏目可用作本项目文献库与综述素材。 ｜ 价值分 2.9/5（★★★☆☆）
全文不可及原因
无 PMCID 且 OpenAlex / Unpaywall 未提供可下载 OA PDF
原文题录
- 中文题名：钙化性主动脉瓣疾病中的细胞衰老：我们准备好用 senolytics 了吗
- 英文标题：Cellular senescence in calcific aortic valve disease: are we ready for senolytic therapy?
- 期刊与标识：Mol Biol Rep · PMID 42965583 · DOI 10.1007/s11033-026-13036-7 · EDAT 2026-10-31